Skip to main content
. 2017 Jun 7;8(32):53288–53301. doi: 10.18632/oncotarget.18395

Figure 4. Analysis of EGFR, ERK and AKT total and phosphorylated in SCC25 (highly sensitive) and HN13 cell lines (resistant) by Western Blot.

Figure 4

EGF ligand was used at 10 ng/mL for 10 minutes. CTR: control; CTX: cetuximab at 50 or 100 μg/mL; AFA: afatinib and AST: allitinib at 0.01 or 0.1 μM.